Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rituximab biosimilar SIBP-02
- Development stage
- Phase 3
- Lead developer
- Shanghai Institute of Biological Products
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SIBP-02 is a biosimilar of rituximab, a chimeric monoclonal antibody that targets the CD20 antigen found on the surface of B lymphocytes. By binding to CD20, it induces B-cell lysis through mechanisms such as antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct induction of apoptosis. SIBP-02 is developed for use in hematological malignancies where CD20-positive B cells are implicated, including diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL), and follicular lymphoma. The drug has been developed by Shanghai Institute of Biological Products, a subsidiary of Sinopharm[2][5][6].
- Other names
- rituximab biosimilar SIBP-02
02
Targets
Beyond the preview
Go deeper on rituximab biosimilar SIBP-02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rituximab biosimilar SIBP-02.